Nebivolol Stada (Nebivolol)

Nebivolol is indicated for cardiovascular conditions, primarily hypertension and heart failure.

• Hypertension: lowers blood pressure by reducing heart rate and peripheral vascular resistance.
• Heart failure (when indicated): improves cardiac output and reduces symptoms in patients with reduced ejection fraction.
• Left ventricular dysfunction: contributes to better ventricular performance as part of heart‑failure management.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing sympathetic stimulation of the heart. In addition, it stimulates endothelial nitric oxide synthase, enhancing nitric oxide release, which promotes vasodilation and further reduces peripheral resistance, leading to lowered blood pressure and heart rate.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Bradycardia
• Nausea
• Peripheral edema

Serious or Rare Side Effects

• Severe bradycardia
• Marked hypotension
• Bronchospasm in patients with reactive airway disease
• Atrioventricular block
• Allergic reactions such as rash or angioedema
• Hepatic dysfunction

When prescribing Nebivolol, clinicians should consider several safety measures.

• Blood pressure monitoring: ensure adequate control without excessive hypotension.
• Cardiac function assessment: evaluate for bradyarrhythmias before initiation.
• Respiratory caution: avoid in patients with severe asthma or COPD.
• Concomitant beta‑blockers: do not combine with other β‑blockers without specialist advice.
• Renal/hepatic impairment: dose adjustment may be required in moderate to severe dysfunction.
• Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Other beta‑blockers: additive negative chronotropic effects.
• Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block.
• Potent CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma levels.
• Clonidine abrupt withdrawal: can precipitate severe hypertension.
• Non‑selective beta‑blockers: heightened bradycardia risk.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor electrolytes and blood pressure.
• ACE inhibitors/ARBs: watch for additive hypotensive effect.
• NSAIDs: may reduce antihypertensive efficacy.
• Anti‑arrhythmic agents: potential for conduction disturbances.
• Antidiabetic drugs: nebivolol may mask hypoglycaemic symptoms.